Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update
– Enzo Life Sciences reports revenue of $7.1 million and 9% growth in Q1 FY 2023, excluding FX
– Engagement with investment bank to provide advisory services including the evaluation of strategic alternatives for the Company is progressing well.
Related news for (ENZ)
- LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
- LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
- Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction
- Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
- LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights